MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

NCT00866177 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

167

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage III Skin Melanoma
Stage IV Skin Melanoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selumetinib

Sponsor

National Cancer Institute (NCI)